Modality
Nanobody
MOA
CDK4/6i
Target
TYK2
Pathway
Wnt
GBMWilms
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
Jan 2019
Phase 2Current
NCT05418190
407 pts·Wilms
2019-01→TBD·Terminated
407 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-133mo agoPDUFA· Wilms
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Termina…
Catalysts
PDUFA
2026-01-13 · 3mo ago
Wilms
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05418190 | Phase 2 | Wilms | Terminated | 407 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |